The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012
Restricted accessResearch articleFirst published online August, 2015
The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012
In acute coronary syndrome, the use of intravenous insulin infusions (IVII) to control hyperglycaemia is based on limited evidence of survival benefit.
Aims:
To compare 7 day survival for patients receiving IVII compared with those receiving routine care to control admission hyperglycaemia (>=11 mmol/l) in acute coronary syndrome.
Methods and results:
We used matched propensity analysis to examine observational data from the MINAP database between 2008 and 2012. We matched 5974 pairs of patients. We separately examined outcomes for ST elevation (STEMI) and non ST segment elevation (NSTEMI) infarctions, and those without known diabetes and those with type 2 diabetes. Survival benefit from the use of IVII was seen only in patients with STEMI not known to have diabetes at admission (adjusted hazard ratio (HR) 0.77 (95% confidence interval (CI) 0.64–0.92), p=0.005). Those with STEMI and existing type 2 diabetes who received IVII showed similar outcomes to routine care (HR 0.99 (95% CI 0.80–1.23), p=0.931). In patients with NSTEMI IVII was associated with significantly worse adjusted 7 day survival outcome than routine care, regardless of diabetes status; for those without known diabetes, HR 1.50 (95% CI 1.04–2.16), p=0.029, and for those with type 2 diabetes, HR 1.35 (95% CI 1.08–1.70), p=0.010.
Conclusion:
As used in current clinical practice to treat hyperglycaemia in acute coronary syndromes, IVII appears to be of benefit only for patients with STEMI who are not known to have diabetes. IVII is associated with adverse early outcomes in patients with NSTEMI.
StrandersIDiamantMvan GelderRE. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med2004; 164: 982–988.
2.
FooKCooperJDeanerA. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart2003; 89: 512–516.
3.
KosiborodMRathoreSSInzucchiSE. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: Implications for patients with and without recognized diabetes. Circulation2005; 111: 3078–3086.
4.
KosiborodMInzucchiSEKrumholzHM. Glucometrics in patients hospitalized with acute myocardial infarction: Defining the optimal outcomes-based measure of risk. Circulation2008; 117: 1018–1027.
5.
GoyalAMahaffeyKWGargJ. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: Results from the CARDINAL study. Eur Heart J2006; 27: 1289–1297.
6.
KosiborodMInzucchiSEKrumholzHM. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med2009; 169: 438–446.
7.
MalmbergKRydénLEfendicS. on behalf of the DIGAMI Study Group. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol1995; 26: 57–65.
8.
MalmbergKRydénLWedelH. for the DIGAMI2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J2005; 26: 650–661.
9.
CheungNWWongVWMcLeanM. The hyperglycemia: Intensive insulin infusion in infarction (HI-5) study: A randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care2006; 29: 765–770.
10.
DeedwaniaPKosiborodMBarrettE. American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: A scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation2008; 117: 1610–1619.
11.
National Institute for Health and Clinical Excellence. NICE Clinical Guideline 130 (2011). Hyperglycaemia in acute coronary syndromes: Management of hyperglycaemia in acute coronary syndromes, www.NICE.org.uk/guidance/CG130 (2011, accessed 16 December 2013).
12.
StegPGJamesSKAtaraD. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J2012; 33: 2569–2619.
13.
GarberAJMoghissiESBransomeED Jr. American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract2004; 10: 77–82.
14.
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J2013; 34: 3035–3087.
15.
HerrettESmeethLWalkerLfor the MINAP Academic Group. The Myocardial Ischaemia National Audit Project (MINAP). Heart2010; 96: 1264–1267.
16.
SimmsADReynoldsSPieperK. Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003–2009: National Institute for Cardiovascular Outcomes Research (NICOR). Heart2013; 99: 35–40.
17.
BirkheadJSWestonCFMChenR. Determinants and outcomes of coronary angiography after non-ST-segment elevation myocardial infarction. A cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Heart2009; 95: 1593–1599.
18.
AltmanDGBlandJM. Interaction revisited: The difference between two estimates. BMJ2003; 326: 219.
19.
ValgimigliMMerliEMalaguttiP. Endothelial dysfunction in acute and chronic coronary syndromes: Evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys2003; 420: 255–261.
20.
EspositoKNappoFMarfellaR. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation2002; 106: 2067–2072.
21.
UndasAWiekIStêpieńE. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care2008; 31: 1590–1595.
22.
KuliczkowskiWGąsiorMPresD. Effect of glycaemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol2012; 110: 331–336.
23.
De MulderMUmansVACornelJH. Intensive glucose regulation in hyperglycemic acute coronary syndrome. Results of the Randomized BIOMarker Study to Identify the Acute Risk of a Coronary Syndrome–2 (BIOMArCS-2) Glucose Trial. JAMA Intern Med2013; 173: 1896–1904.
24.
WestonCWalkerLBirkheadJS. Early impact of insulin treatment on mortality for hyperglycaemic patients without known diabetes who present with an acute coronary syndrome. Heart2007; 93: 1542–1547.
25.
ChanAWChewDPBhattDL. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol2002; 89: 132–136.
26.
ZhaoJLYangYJZhangYH. Chronic pre-treatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty. Clin Cardiol2007; 30: 130–134.
27.
IwakuraKItoHKawanoSOkamuraA. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J2006; 27: 534–539.
28.
NathanDMBuseJBDavidsonMB. Medical management in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2009; 32: 193–203.
29.
National Institute for Health and Clinical Excellence. NICE Clinical Guideline 87 (2009). Type 2 diabetes: The management of type 2 diabetes, www.nice.org.uk/CG87 (2009, accessed 16 December 2013).
30.
WhittingtonHJHallARMcLaughlinCP. Chronic metformin associated cardioprotection against infarction: Not just a glucose lowering phenomenon. Cardiovasc Drugs Ther2013; 27: 5–16.
31.
ZhaoJLFanCMYangYJ. Chronic pre-treatment with metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction. Cardiovasc Ther2013; 31: 60–64.
32.
LexisCPWieringaWGHiemstraB. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther2014; 28: 163–171.
33.
DeFronzoRAHendlerRChristensenN. Stimulation of counter-regulatory hormonal responses in diabetic man by a fall in glucose concentration. Diabetes1980; 29: 125–131.
34.
GillGVWoodwardACassonIF. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes: The ‘dead in bed’ syndrome revisited. Diabetologia2009; 52: 42–45.
35.
GallowayPJThomsonGAFisherBM. Insulin-induced hypoglycemia induces a rise in C-reactive protein. Diabetes Care2000; 23: 861–862.
36.
ACCORD Study Group. GersteinHCMillerMEGenuthS. Long term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med2011; 364: 818–928.
37.
ZoungasSPatelAChalmersJ. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med2010; 363: 1410–1418.
38.
MellbinLGMalmbergKWaldenströmA, for the DIGAMI2 investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: A report from the DIGAMI 2 trial. Heart2009; 95: 721–727.
39.
KosiborodMInzucchiSEGoyalA. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA2009; 301: 1556–1564.
40.
Van den BergheGWilmerAHermansG. Intensive insulin therapy in the medical ICU. N Engl J Med2006; 354: 449–461.
41.
The NICE-SUGAR Study Investigators. FinferSLiuBChittockDR. Intensive versus conventional glucose control in critically ill patients. N Engl J Med2009; 360: 1283–1297.
42.
DahabrehIJSheldrickRCPaulusJK. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J2012; 33: 1893–1901.
